Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer

NCT01837095 is registered in ClinicalTrials.gov with Polyphor Ltd. as lead sponsor.

NCT NCT01837095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01837095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer
Lead sponsor
Polyphor Ltd.
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2013
Completion date
August 31, 2018
Enrollment
54 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer